Compare FTK & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTK | AURA |
|---|---|---|
| Founded | 1985 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 522.1M | 419.5M |
| IPO Year | 1997 | 2021 |
| Metric | FTK | AURA |
|---|---|---|
| Price | $16.88 | $6.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $20.00 | $19.00 |
| AVG Volume (30 Days) | 201.9K | ★ 299.9K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 147.06 | N/A |
| EPS | ★ 0.84 | N/A |
| Revenue | ★ $136,092,000.00 | N/A |
| Revenue This Year | $13.33 | N/A |
| Revenue Next Year | $16.38 | N/A |
| P/E Ratio | $20.71 | ★ N/A |
| Revenue Growth | ★ 214.53 | N/A |
| 52 Week Low | $6.68 | $4.73 |
| 52 Week High | $20.41 | $7.68 |
| Indicator | FTK | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 53.87 | 52.82 |
| Support Level | $15.89 | $5.94 |
| Resistance Level | $17.67 | $7.04 |
| Average True Range (ATR) | 0.82 | 0.33 |
| MACD | 0.17 | -0.03 |
| Stochastic Oscillator | 69.33 | 33.94 |
Flotek Industries Inc is a technology-driven specialty chemistry and data company. It has two reportable segments: Its Chemistry Technologies segment includes specialty chemistries, logistics and technology services. It also include integrated oil and gas companies, oilfield services companies, independent oil and gas companies, national and state-owned oil companies, and international supply chain management companies. The Data Analytics segment provides analytical measurement solutions and deliver real-time information and insights to customers to enable optimization of operations and reduction of emissions and their carbon intensity. Key revenue comes from its Chemistry Technologies segment.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.